Vitamin B4 Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Animal Feed, Food Industry, Pharmaceutical, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 789.02 Million
CAGR (2026-2031)	4.13%
Fastest Growing Segment	Direct
Largest Market	North America
Market Size (2031)	USD 1005.87 Million

Market Overview

The Global Vitamin B4 Market is projected to grow from USD 789.02 Million in 2025 to USD 1005.87 Million by 2031 at a 4.13% CAGR. Vitamin B4, chemically identified as adenine, is a fundamental purine nucleobase that plays a critical role in protein synthesis and cellular energy transfer, serving as a key component of DNA, RNA, and ATP. The global market is primarily supported by the expanding pharmaceutical sector, which utilizes high-purity adenine for antiviral drugs and immunosuppressive therapies, and the animal nutrition industry, where it is valued as a feed additive to enhance livestock immunity and growth rates. These drivers are distinct from general wellness trends, relying instead on specific industrial and medicinal requirements for efficient metabolic function in both humans and animals.

However, a significant challenge impeding market expansion is the volatility of raw material costs and supply chain complexities, which create pricing instability for manufacturers and end-users. Illustrating the robust demand trajectory in a primary application sector, according to the China Feed Industry Association, in 2025, total industrial feed production increased by 7.7 percent during the first half of the year compared to the same period in the previous year. While this data underscores strong downstream consumption, the unpredictable nature of input expenses remains a persistent obstacle to consistent market growth.

Key Market Drivers

Increasing utilization in animal feed additives for livestock health constitutes a dominant force in the global Vitamin B4 market. As a vital purine nucleobase, adenine is increasingly incorporated into feed premixes to bolster immune system function and optimize metabolic energy transfer in poultry and swine, directly addressing the industry's need for efficient protein conversion. This reliance is intensified by the recovery in global livestock production metrics, which necessitates higher volumes of fortified feed to maintain yield targets. According to Alltech, May 2025, in the '2025 Agri-Food Outlook', global feed production increased by 1.2% to 1.396 billion metric tons in 2024, signaling a resurgence in additive consumption. Furthermore, robust downstream activity supports this trend; according to the National Bureau of Statistics of China, in 2025, total red meat and poultry production reached 96.63 million tons for the preceding year, underscoring the sustained scale of raw material requirements for livestock sustenance.

The expansion of pharmaceutical applications and therapeutic formulations serves as the second critical driver, leveraging adenine’s function as a precursor for antiviral drugs and immunosuppressive agents. Manufacturers are prioritizing high-purity grades of Vitamin B4 to meet the rigorous standards of the biopharmaceutical sector, particularly for nucleoside analog synthesis used in treating viral infections and chronic diseases. This shift toward specialized medicinal use is reflected in the financial performance of key contract development and manufacturing organizations that process such intermediates. According to Lonza, March 2025, in the 'Annual Report 2024', their Small Molecules division reported sales growth of 9.3% compared to the prior year, driven by high commercial demand for complex active pharmaceutical ingredients. This trajectory highlights the market's strategic pivot toward high-value life science applications, distinct from commodity-level feed uses.

Download Free Sample Report

Key Market Challenges

The volatility of raw material costs and supply chain complexities stands as a substantial barrier to the stability and expansion of the Global Vitamin B4 Market. Vitamin B4 manufacturers rely heavily on a consistent supply of chemical precursors and energy-intensive synthesis processes to produce high-purity adenine. When upstream input costs fluctuate unpredictably, producers face significant difficulties in maintaining stable pricing structures, which directly impacts their ability to secure long-term contracts with downstream buyers in the pharmaceutical and animal nutrition sectors. This economic uncertainty forces manufacturers to operate with reduced margins or pass elevated costs to end-users, frequently leading to delayed procurement decisions and reduced market liquidity.

The impact of these cost pressures is evident in the broader chemical manufacturing landscape, which serves as the foundation for adenine production. According to the European Chemical Industry Council, in 2025, capacity utilization in the chemical sector dropped to 74.6 percent as producers struggled with energy and feedstock costs that remained three times higher than those in competing regions like the United States. Such structurally high and unstable operational expenses deter essential investment in production capacity and innovation, effectively hampering the overall growth trajectory of the Vitamin B4 market.

Key Market Trends

The transition toward sustainable enzymatic synthesis methods represents a fundamental shift in Vitamin B4 manufacturing, driven by the imperative to reduce the environmental footprint and energy consumption of traditional chemical processes. Producers are increasingly replacing conventional chemical catalysis with biocatalytic systems, which offer higher specificity and reduced hazardous waste generation, crucial for meeting stringent environmental regulations in major production hubs. This industrial pivot is validated by the robust financial performance of leading biosolution providers who supply the necessary enzymatic platforms. According to Novonesis, February 2025, in the 'Annual Report 2024', the company delivered 8% organic sales growth, underscoring the accelerating industrial adoption of biological manufacturing technologies over legacy chemical methods.

Simultaneously, the market is witnessing a distinct expansion into abiotic stress-resilient plant biostimulants, where adenine is utilized to enhance crop tolerance against extreme weather conditions such as drought and salinity. Unlike traditional fertilizer applications, this trend focuses on modulating plant physiological pathways to secure yield stability, creating a high-value niche for Vitamin B4 beyond animal nutrition. This growing reliance on advanced agricultural biologicals is evident in the sales volume of major agriscience corporations. According to Corteva Agriscience, November 2025, in the 'Third Quarter 2025 Results', crop protection sales volume increased by 7% during the first nine months of the year, a growth trajectory specifically attributed to the rising global demand for new biological formulations and stress-management products.

Segmental Insights

The Direct sales channel is currently expanding more rapidly than other segments within the Global Vitamin B4 Market. This trend is primarily driven by the increasing preference of pharmaceutical and animal feed manufacturers to establish direct supply agreements with producers. By bypassing intermediaries, large-scale buyers ensure stricter adherence to purity standards and regulatory compliance mandated by authorities such as the Food and Drug Administration. Furthermore, this direct engagement model offers significant cost advantages through streamlined logistics and fosters stronger, long-term business partnerships capable of meeting specific formulation requirements with greater precision.

Regional Insights

North America holds the leading position in the Global Vitamin B4 Market, primarily driven by its established healthcare infrastructure and a strong pharmaceutical sector. The region experiences high demand for dietary supplements and functional foods, stemming from rising consumer awareness regarding preventive wellness and energy metabolism. Additionally, the extensive use of Adenine in medical research and therapeutic formulations accelerates market expansion. A structured regulatory environment, overseen by the United States Food and Drug Administration, ensures product safety and quality, thereby fostering a stable commercial climate for manufacturers and key industry stakeholders.

Recent Developments

• In April 2025, Star Lake Bioscience released its 2024 annual report, disclosing a substantial year-on-year increase in net profits attributable to shareholders, which reached approximately RMB 943 million. The company, a key manufacturer in the global adenine market, attributed this financial performance to a surge in sales volume for its core products and a reduction in raw material costs such as corn and coal. This robust growth reflected a recovery in the broader nucleoside and amino acid sectors, positioning the company to further consolidate its market share in the pharmaceutical and feed additive industries.
• In October 2024, Jubilant Ingrevia revealed plans to expand its production capabilities for Vitamin B4 (Choline Chloride) and other specialty ingredients during its investor presentation for the second quarter of the fiscal year. The company highlighted that the capital expenditure for a new GMP-compliant facility dedicated to food-grade Vitamin B4 was in the final stages of planning, aiming to strengthen its position as a dominant domestic player in India. Furthermore, the management emphasized that the expansion was strategically timed to leverage favorable market conditions created by the European Union's anti-dumping investigation into Chinese choline chloride imports, which was expected to open new export opportunities.
• In May 2024, Balchem Corporation launched a new proprietary ingredient named Optifolin+, described as a bioactive choline-enriched folate salt designed to support cellular health and methylation. This product introduction represented a strategic innovation in the nutrition market, combining Vitamin B4 (choline) with L-5-methyltetrahydrofolate to deliver enhanced stability and solubility for supplement manufacturers. The launch aimed to capitalize on the growing demand for prenatal, heart, and brain health solutions by providing a highly bioavailable form of these essential nutrients, thereby expanding the company's portfolio in the human nutrition segment.
• In April 2024, Protara Therapeutics announced a significant regulatory milestone following an alignment with the U.S. Food and Drug Administration (FDA) regarding the registrational path for its intravenous Choline Chloride, a Vitamin B4 therapy. The company disclosed that it would proceed with a Phase 2b/3 clinical trial to assess the safety and efficacy of the product for patients dependent on parenteral support who are at risk of choline deficiency and liver injury. This development marked a critical step forward for the pharmaceutical application of Choline Chloride, addressing a substantial unmet medical need for patients unable to absorb sufficient nutrients through oral or enteral routes.

Key Market Players

• Shandong Yinfeng Biological Technology Co., Ltd.
• GHW International
• St. Gabriel CC Company, LLC
• Balchem Corporation
• Jubilant Ingrevia Limited
• Hangzhou Donglou Bio-Nutrition Co., Ltd.
• Shandong NB Technology Co Ltd.,
• Shandong Jujia Biotech Co.,Ltd
• Liaoning Biochem Co., Ltd
• Shandong Aocter Chemical Co.,Ltd.

By Sales Channel	By End Use	By Region
Direct Indirect	Animal Feed Food Industry Pharmaceutical Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Vitamin B4 Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Vitamin B4 Market, By Sales Channel:

• Direct
• Indirect

• Vitamin B4 Market, By End Use:

• Animal Feed
• Food Industry
• Pharmaceutical
• Others

• Vitamin B4 Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE